CEConversations

Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs).  Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the number of patients with cancer who develop a VTE at some point during their treatment (around 15%).  CA-VTE is associated with decreased survival, increased morbidity and hospitalization, and the potential delay or interruption of systemic anti-cancer therapy.  During this series, our faculty will expand clinician knowledge of VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.In this 60-minute program, expert faculty will review CA-VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.  Clinicians can expect to gain valuable insight that will help them understand and overcome barriers to adequate anticoagulant therapy for patients with cancer.

This podcast focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events. To claim credit, visit: https://www.ceconcepts.com/activity/actionable-strategies-in-community-oncology-to-achieve-equity-in-triple-negative-breast-cancer-3/

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here:  https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/This podcast reviews the etiology and epidemiology of obesity, as well as prominent unmet needs and barriers to treatment optimization as a means of providing foundational context for learners. Expert faculty will then lead attendees on an immersive, deep dive through the established paradigm and the preponderance of emerging data for novel weight-loss therapeutics, most notably the GLP-1 agonists and the GLP-1/GIP agonists. The session will conclude with a case-based segment, in which attendees will get to apply the principles they have learned to real-world clinical scenarios, address practical weight-loss challenges, and highlight the instrumental role of the primary care physician as a gatekeeper for the obesity management team.  Request credit here: https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/Supported through an independent educational grant from Lilly.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here:  https://www.ceconcepts.com/igan-ee-podcastThis activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they've learned to real-world clinical scenarios.Supported through an independent educational grant from Travere.

This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment sequencing and the role of antibody-drug conjugates (ADCs) in subsequent lines of therapy for advanced disease. To conclude the session, activity attendees will get to apply the therapeutic principles they've learned to real-world clinical scenarios which will focus on patient-centric treatment selection and sequencing, as well as recognition, mitigation, and management of treatment-related adverse events.1.50 AMA PRA Category 1 Credit™1.50 ParticipationCollect credit: https://www.ceconcepts.com/gu-cancer23-podcast

This educational activity will meet nephrology nurses where they are and provide them with expert insights into CKD-aP prevalence, patient burden, therapeutic rationale, and pivotal principles for safely and effectively integrating novel treatments into practice. The role of the nurse as a premier patient-facing care provider will be emphasized throughout, and notable focus will be placed on CKD-aP symptom recognition, patient education, drug administration, and toxicity management.Collect credit: https://www.ceconcepts.com/ckd-ch-podcast

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/navigating-ckd-podcast#group-tabs-node-course-default1To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events. Erythropoietin-stimulating agents (ESAs) are associated with significant cardiovascular safety-related concerns, but the emergence of the oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may improve erythropoiesis without the undesirable downstream effects of ESAs. However, HIF-PHIs place in therapy has not yet been fully elucidated. Here, join the interprofessional team of Dr. Ajay Singh, Dr. Jane Davis, and Dr. Calvin Meaney as they explore an incisive review of current CKD-anemia treatment and diagnostic challenges, as well as the evidentiary base for HIF-PHI utilization in CKD-anemia that establishes context for the future of these agents. In conclusion, a practical discussion of real-world patient case scenarios will be presented, to provide learners with context of the multiple comorbidities, complexities, diagnostic challenges, and barriers to appropriate treatment of CKD-anemia.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/hk-ch-podcast Learning ObjectivesAppraise key mechanisms of potassium homeostasis and review patient-centric risk factors for hyperkalemia.Discuss the prevalence and clinical gravity of hyperkalemia, with emphasis on acute care challenges and the morbidity/mortality impact of suboptimal renin-angiotensin-aldosterone system inhibitor (RAASi) utilization in the chronic setting.Evaluate novel K+ binder (patiromer and sodium zirconium cyclosilicate [SZC]) pharmacology, safety and efficacy profiles, and differential clinical utility across the hyperkalemia treatment continuum.Examine evolving clinical trial data in support of patiromer and SZC for hyperkalemia management, with a particular focus on usage in acute care and in-hospital settings.Use a case-based approach to design treatment strategies using novel K+ binders that the interprofessional care team can employ to improve hyperkalemia outcomes in the hospital.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/sitc22-podcastThis session will review the totality of emerging evidence for immune checkpoint inhibitors (ICIs) in the hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) management calculus. Faculty will highlight the paradigmatic change ICIs have achieved, emphasize key teaching points for real-world use, and evaluate adaptive clinical trial designs and study schemas being used to investigate ICI-based treatment regimens in HCC and BTC on a prospective basis.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-iron-expert-exchange-podcastIn this Expert Exchange-based format, activity attendees will be immersed in a lively discussion between key thought leaders in the world of HF. Expert discussion will include an exploration of clinical trial data for intravenous (IV) iron therapies in HF and recently-updated expert consensus HF management guidelines, with emphasis on the emerging role of IV iron on improved clinical endpoints in HFrEF. Key teaching points up for debate include the safety and efficacy profiles of next-generation IV iron products, established and emerging clinical trial data in HF, and a comparative analysis of currently-available IV iron products.

To receive up to 2.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/2022chest-podcast This dynamic live symposium, led by top experts in the field of pulmonary medicine and NSCLC, will take attendees on a deep dive into the sentinel role of the pulmonologist in the NSCLC management paradigm, exploring adaptive mechanisms to optimize collaborative strategies in a patient centric manner.Learning ObjectivesReview the sentinel placement of the pulmonologist in the management of NSCLC, including their principal role in diagnostics, disease staging, and molecular testing.Evaluate clinical and patient-value driven factors that may help inform nodule evaluation and diagnostic strategies for pulmonologists, thus ensuring “the right tissue in the right amount from the right place for the right patient.”Demonstrate knowledge of guideline recommendations and practical considerations for the use of EBUS-TNBA techniques by pulmonologists, emphasizing the fundamentals of safely and effectively obtaining adequate tissue for diagnosis and molecular characterization.Describe the evolving role of targeted therapy and immunotherapy in NSCLC and analyze currently FDA-approved therapeutics across the NSCLC disease continuum, highlighting the role of molecular testing for guiding treatment and individualizing patient care.Explore the established utility of next-generation sequencing (NGS) and discuss the potential for emerging “next-generation” biomarkers in the NSCLC management paradigm.Apply patient-centric, evidence-supported collaborative care strategies to real-world, case-based scenarios in order to elucidate the pivotal role of the pulmonologist on the multidisciplinary team across the NSCLC continuum of care.Presented by Creative Educational Concepts, LLC.Supported through an independent educational grant from AstraZeneca.

Learning ObjectivesReview the epidemiology and clinical characteristics of HR+, HER2- early-breast cancer (EBC), and identify patients at an elevated risk of disease recurrence as a means of guiding treatment.Appraise the current treatment landscape in HR+, HER2- EBC, including the established and emerging evidentiary base for novel therapies in the adjuvant setting, expert consensus guidelines, and FDA-approved indications.Recognize treatment-related adverse events associated with oral therapies used in HR+, HER2- EBC and implement evidence-supported mitigation and management protocols.Using real-world patient case examples, design on-label treatment plans for HR+, HER2- EBC at high risk for recurrence, emphasizing the critical need for effective communication and coordination strategies among the multidisciplinary community-based breast cancer care team.Evaluate adaptive approaches for promoting adherence and persistence to oral anticancer therapies, highlighting common reasons for noncompliance and the impact of patient counseling and shared decision-making (SDM).Presented by:Hope S. Rugo, MDProfessor, Division of Hematology/OncologyDirector, Breast Oncology Clinical Trials EducationUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, CAPresented by Creative Educational Concepts, LLC.Supported through an independent educational grant from Lilly.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ovarian-gr-podcast Learning ObjectivesReview recent updates to national guideline recommendations in ovarian cancer treatment and testing and discuss health equity issues that may hinder ovarian cancer patients from receiving the current standard of care.Appraise landmark and emerging safety and efficacy data with PARP inhibitors in the treatment of ovarian cancer, with a focus on most recent recommendations and rationale for the use of PARP inhibitors in the first-line maintenance setting.Analyze the unique toxicity profiles among PARP inhibitor therapies and important considerations for both monitoring and managing adverse events.Use an interactive, multi-disciplinary approach to discuss challenging cases regarding the appropriate selection of treatment based on clinical data and guidelines, the use of predictive biomarkers, the management of adverse events, and strategies to mitigate modifiable healthcare disparities in ovarian cancer patients.Presented by Creative Educational Concepts, LLC.Supported through an independent educational grant from GSK.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-gr-podcast#group-tabs-node-course-default1Learning ObjectivesReview the clinical gravity and foundational pathophysiology of iron deficiency anemia (IDA) in pediatric patients, with an emphasis on patient impact and the need for treatment.Evaluate the evolving clinical trial evidentiary base for intravenous (IV) iron as IDA management in pediatric patients, including a summary of recent FDA approvals and updated label indications for IV iron therapies.Discuss practical aspects of IV iron usage in the pediatric setting, including appropriate dosing, safety considerations, and clinician adherence to evidence-based IDA treatment standards.Use a real-world, case-based format to design evidence-supported strategies for recognizing, diagnosing, treating, and evaluating IDA in pediatric patients, focusing on the interpolation of IV iron into the management paradigm.Presented By:Jacquelyn M. Powers, MD, MSAssistant Professor of PediatricsAssociate Chief, Pediatric HematologyBaylor College of MedicineTexas Children's Cancer and Hematology CentersHouston, TX

Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC. During their presentations and discussion, they will examine the established treatment landscape for unresectable, stage III NSCLC as well as the emerging role of immunotherapy, and practical clinical considerations for anticipating, mitigating, and managing immune-related adverse events.Presented by Creative Educational Concepts, LLC.Supported through an independent educational grant from AstraZeneca. 

Learning ObjectivesReview the formative facets of iron absorption and metabolism, including the practical distinctions between functional and absolute iron deficiency, with expert analysis of how these principles dictate treatment approaches.Summarize the multifactorial etiologies and complex pathophysiology of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA), emphasizing the implications of CRA/CIA on oncologic outcomes and patient-centric metrics.Appraise completed, ongoing, and planned clinical trials of IV iron products in CRA/CIA, highlighting the established ability of these agents to enhance hematopoietic response rates, decrease transfusion burden, and improve patient outcomes.Discuss how next-generation IV iron products have dramatically improved upon the safety profiles of earlier generation agents, particularly with respect to severe hypersensitivity reactions.Review current expert consensus guidelines for CRA/CIA management from ASCO/ASH, NCCN, and ESMO.  Use real-world patient cases to evaluate evidence-supported strategies that members of the multidisciplinary and interprofessional cancer care team can use to safely and effectively implement IV iron into clinical practice.Compare and contrast the unique clinical utility of currently-approved IV iron agents, emphasizing the impact of differential safety profiles on treatment decisions.Investigate the clinical implications of IV iron-associated hypophosphatemia in all patients, but especially in those with cancer and/or those actively receiving chemotherapy.Presented by Creative Educational Concepts, LLC.Supported through an independent educational grant from Pharmacosmos Therapeutics, Inc.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/cras-podcastAll clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron. Unfortunately, clinician hesitancy in prescribing IV iron, largely due to adverse effects associated with earlier formulations, must be overcome before the full benefit of IV iron in CRAS can be realized. Join Drs. Matthew Weir and Javed Butler as they address CRAS pathophysiology, examine applicable expert consensus guidelines, and review current evidence for treatment. Practical, case-based elements will be offered that provide learners with real-world examples of IV iron safety, efficacy, and the need for multidisciplinary (nephrologist-cardiologist-PCP) care.Presented by Creative Educational Concepts, LLC.Supported through an independent educational grant from American Regent.

 To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://ce.ceconcepts.com/EGFR1This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC. These data will be placed in context of the established paradigm, with key scientific messages and pivotal points highlighted for audience takeaway. The session will conclude with a patient-led roundtable evaluating the multifarious burden of financial toxicity on optimal and equitable outcomes in NSCLC.Supported through an independent educational grant from EQRx International, Inc.Presented by Creative Educational Concepts, LLC.

Learning ObjectivesDiscuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies community-based clinicians can employ to promote equitable care and outcomes for all patients.Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, including dosing, administration, and toxicity management, for community oncology clinicians using ADCs to manage TNBC. Examine completed, ongoing, and planned clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus and the effective integration of socioeconomic and other non-biologic factors into equitable cancer care.    Supported by independent educational grant from Gilead.Presented by Creative Educational Concepts, LLC.

To receive up to 1.5 ANCC contact hours, please complete the evaluation and request form here: https://ce.ceconcepts.com/ONS2022This symposium will explore the latest ovarian cancer guideline recommendations and recent evidence for PARP inhibitors in treatment and maintenance settings. The nurse's role in facilitating access to quality care for those with disparities, the unique toxicity profiles of PARP inhibitors, and how to mitigate, anticipate, and manage toxicities that may arise will also be discussed. Attendees will interact with the expert faculty through patient cases with audience response questions incorporated throughout.Supported through an independent educational grant from GlaxoSmithKline.Presented by Creative Educational Concepts, LLC.

Visit this link to complete the CE request form & evaluation:  https://www.ceconcepts.com/DLBCL-GR-PodcastThis activity will review the failure rates of traditional therapies for DLBCL, such as R-CHOP, and evaluate patient-centric factors that contribute to disease progression and/or relapse. Expert faculty will then guide attendees through an evidence-based examination of the exigent need for more effective front-line therapeutic options in DLBCL, emphasizing practical clinical pearls and notable distinguishing features of novel and emerging treatment agents and their potential to optimize patient outcomes.Supported by an independent educational grant from Genentech.

This activity will review how social determinants of health have led to inequities and disparate outcomes in HF. Attendees will take part in an expert-led exploration of current treatment guidelines, with an emphasis on HFrEF, and a review of emerging novel therapeutics. Learners will review real-world cases, empowering them to effectively interpolate novel agents into established guideline-directed medical therapy (GDMT) protocols and promote the closure of outcomes chasms driven by disparities in care.Supported by an independent educational grant from Merck.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-iron-podcast This Medical Moments webinar will review all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The activity will begin with a brief primer on iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment approaches. An appraisal of the foundational pathophysiology of CRA will follow, with a central emphasis on the role of hepcidin in a hyperinflammatory disease state like cancer, and the resultant rationale for the preferential use of intravenous (IV) iron versus oral iron modalities in patients with cancer. Finally, the preeminent emphasis of the session will be an incisive exploration of completed, ongoing, and planned clinical trials of IV iron for CRA/CIA, including systematic reviews and meta-analyses, as well as recently-reported pivotal trials, such as IRON-CLAD.Supported through an independent educational grant from American Regent.

Our hosts interview two pharmacists, both of whom have expertise in the realms of vaccine supply chain management, distribution, and administration, regarding the myriad challenges and practical hurdles posed by a global pandemic - and key strategies to overcome them. Guests: Joel Thornbury, President, Kentucky Pharmacists Association (KPhA); Owner, Nova Pharmacy; Brooke Hudspeth, PharmD, Associate Professor and Chief Practice Officer, University of Kentucky College of Pharmacy

Our hosts interview an immunology researcher and vaccine expert regarding how effectively harnessing the immune system possesses the power to defeat the pandemic and restore normalcy to the world. Practical issues, such as the role of health inequities and social determinants of health, and how/when we can safely travel the world or simply eat at the restaurant down the street, are also addressed.Guest: Vincent Venditto, PhDAssistant ProfessorUniversity of Kentucky College of Pharmacy

An infectious disease pharmacist and an immunology specialty pharmacist discuss current and emerging data about COVID-19 with a renowned virologist. They review where we've been, the current state of affairs as the vaccine supply chain is stretched to capacity on an international scale, and perhaps most importantly--where we can expect to be in 6 months.Episode Guest: Rebecca Dutch, PhD (Hosts: Craig Martin, PharmD, MBA; Dave Feola, PharmD, PhD)